Lopinavir

Contraindicated

Lopinavir Simvastatin Flolipid Explained An increased risk of myopathy or rhabdomyolysis Details Lopinavir Alfuzosin UroXatral Increased alfuzosin concentration and increased risk of torsade de pointes Details Lopinavir Dihydroergotamine Injection DHE-45® Injection An increased risk of dihydroergotamine toxicity including nausea, vomiting, and vasospastic ischemia Details Lopinavir Dihydroergotamine Nasal Spray Migranal An increased risk of dihydroergotamine toxicity including nausea, vomiting, and vasospastic ischemia Details Lopinavir Ketoconazole Topical Extina® Foam Increased serum concentrations of ketoconazole and/or lopinavir/ritonavir; increased risk for QT interval prolongation Details Lopinavir Lovastatin Altocor® An increased risk of myopathy or rhabdomyolysis Details Lopinavir Methylergonovine Methergine An increased risk of methylergonovine toxicity including nausea, vomiting, and vasospastic ischemia Details Lopinavir Midazolam Nasal Spray Nayzilam Increased midazolam plasma concentrations Details Lopinavir Midazolam Injection Nayzilam Increased midazolam plasma concentrations Details Lopinavir Nimodipine Nimotop Increased serum nimodipine concentrations Details

Major

Lopinavir Abametapir Explained Increased exposure of CYP3A4 substrate Details Lopinavir Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Lopinavir Acalabrutinib Calquence Increased acalabrutinib exposure Details Lopinavir Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Lopinavir Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Lopinavir Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Lopinavir Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Lopinavir Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Lopinavir Azithromycin AzaSite An increased risk of QT interval prolongation Details Lopinavir Atorvastatin Atorvaliq Increased atorvastatin exposure with increased risk of myopathy or rhabdomyolysis Details Lopinavir Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Lopinavir Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Lopinavir Amlodipine Amvaz® Reduced amLODIPine exposure Details Lopinavir Avanafil Stendra Decreased avanafil clearance and increased avanafil plasma concentration Details Lopinavir Axitinib Inlyta Increased axitinib plasma concentrations Details Lopinavir Brigatinib Alunbrig Increased brigatinib exposure Details Lopinavir Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Lopinavir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Lopinavir Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lopinavir Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lopinavir Calcifediol Rayaldee Altered serum levels of calcifediol Details Lopinavir Chloroquine Aralen® An increased risk of QT interval prolongation Details Lopinavir Cobimetinib Cotellic Increased cobimetinib exposure Details Lopinavir Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Lopinavir Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Lopinavir Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Lopinavir Dexamethasone Injection Decadron Increased dexAMETHasone exposure Details Lopinavir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Increased dexAMETHasone exposure Details Lopinavir Dofetilide Tikosyn An increased risk of QT interval prolongation Details Lopinavir Dolasetron Anzemet An increased risk of QT interval prolongation Details